• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

    10/4/23 3:22:13 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email
    SC 13G 1 tm2327717d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G*
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2
    (Amendment No. __)*
     
      Aldeyra Therapeutics Inc  
    (Name of Issuer)
     
      COMMON STOCK, PAR VALUE $0.001 PER SHARE  
    (Title of Class of Securities)
     

    01438T 10 6

    (CUSIP Number)

     

      September 28, 2023  
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    Cusip No.

    01438T 10 6

    13G Page 2 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Knoll Capital Management, LLC 

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,595,916

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,595,916

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    3,595,916 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.1%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    LLC

     

     

     Page 2 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 3 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Fred Knoll

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    3,595,916

     

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,595,916

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    3,595,916 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.1%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    IN

     

     

     Page 3 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 4 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Gakasa Holdings, LLC

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,595,916

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,595,916

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    3,595,916 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.1%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    LLC

     

     

     Page 4 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 5 of 8 Pages

     

    Item 1(a).Name of Issuer:

     

    Aldeyra Therapeutics Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    131 Hartwell Avenue, Suite 320, Lexington, MA 02421

     

    Item 2(a).Name of Persons Filing:

     

    Knoll Capital Management LLC (“KCM”)

    Fred Knoll (“Knoll”)

    Gakasa Holdings, LLC. (“Gakasa”)

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The principle business address for each of KCM, Knoll and Gakasa is 201 S. Biscayne Blvd suite 800, Miami, FL 33131

     

    Item 2(c).Citizenship:

     

    KCM is a limited liability company formed and existing under the laws of the State of Florida.

    Knoll is a citizen of the United States.

    Gakasa is a limited liability company organized under the laws of the State of Florida.

     

    Item 2(d).Title of Class of Securities:

     

    Common shares par value 0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    01438T 10 6

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable

     

    (a) ¨Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
         
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

     Page 5 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 6 of 8 Pages

     

    Item 4.Ownership:

     

    Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    As of this filing: Gakasa beneficially owns 3,595,916 Shares of the Issuer’s Common Stock. Each of KCM and Knoll beneficially own 3,595,916 Shares of the Issuer’s Common Stock. KCM has trading authority for Gakasa, and Knoll is the President of KCM.

     

    (b)Percent of Class:

     

    The shares of the Issuer’s Common Stock beneficially owned by each of Gakasa, KCM and Knoll constitute 6.1% of the Issuer’s Common Stock outstanding.

     

    This percentage is calculated based on the company’s 10Q, stating as of August 1, 2023, there were 58,595,850 shares of the registrant’s common stock issued and outstanding.

      

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 3,595,916

     

    KCM, Knoll and Gakasa share the power to vote or direct the vote of those shares of Common Stock owned by Gakasa.

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 3,595,916

     

    KCM, Knoll and Gakasa share the power to dispose of or direct the disposition of those shares of Common Stock owned by Gakasa.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

     Page 6 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 7 of 8 Pages

     

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10.Certifications:

     

    By Signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 

     

     

    Cusip No.

    01438T 10 6

    13G Page 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, I certify (the undersigned certifies) that the information set forth in this statement is true, complete and correct.

     

      KNOLL CAPITAL MANAGEMENT, LLC.
       
      By: /s/ Fred Knoll
    Dated: October 3, 2023 Name: Fred Knoll
      Title: President
       
      /s/ Fred Knoll
    Dated: October 3, 2023 Fred Knoll
       
      GAKASA HOLDINGS, LLC.
      By: Knoll Capital Management, LLC.
       
      By: /s/ Fred Knoll
    Dated: October 3, 2023 Name: Fred Knoll
    Title: President

     

     Page 8 of 8 

     

     

    Get the next $ALDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALDX

    DatePrice TargetRatingAnalyst
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    4/2/2024$10.00Buy
    H.C. Wainwright
    4/27/2022$15.00Buy
    H.C. Wainwright
    12/21/2021$25.00 → $21.00Buy
    Citigroup
    12/21/2021$24.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aldeyra Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00

      4/3/24 7:39:55 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00

      4/2/24 8:09:59 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00

      4/27/22 7:14:02 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      11/14/24 4:50:29 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/14/24 4:52:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

      SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/13/24 4:58:48 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clark William D

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:41:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Clark William D

      3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:21:39 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Perceptive Advisors Llc sold $4,828,000 worth of shares (3,400,000 units at $1.42) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/7/25 6:43:07 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Financials

    Live finance-specific insights

    See more

    $ALDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

      Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

      4/3/25 8:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      10/21/24 8:22:37 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $833,867 worth of shares (177,993 units at $4.68) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/8/24 5:32:55 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $1,934,505 worth of shares (504,272 units at $3.84) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/3/24 5:22:41 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    SEC Filings

    See more
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      5/6/25 7:01:18 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aldeyra Therapeutics Inc.

      DEFA14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:25:44 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aldeyra Therapeutics Inc.

      DEF 14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:19:43 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care